Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays
N. Pencheva, J. Pospišek, L. Hauzerova, T. Barth, P. Milanov · 1999 · British Journal of Pharmacology. 128(3):569–576
What does this source report?
Isolated-tissue assays showed that D-Ala configuration and other sequence modifications altered potency, peptidase resistance and receptor preference. The tested Dalargin profile favored μ activity; this does not settle receptor contributions in every tissue or disease model.
- Population and setting
- Isolated preparations from guinea pig, hamster, mouse, rat and rabbit
- Evidence type
- In vitro
- Preparation
- See the original report; formulation details require verification.
- Source language
- English abstract or source translation
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Animal-tissue bioassays, not a human efficacy or safety trial.
- Dalargin analogues are not interchangeable with the parent peptide.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Selected text reviewed
Source access and review scope
Selected source text and metadata checked; full risk-of-bias review pending.
Recorded source-check date: 2026-10-04. This date does not imply a completed systematic review.
Cite and trace this record
Original source: N. Pencheva, J. Pospišek, L. Hauzerova, T. Barth, P. Milanov. Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays British Journal of Pharmacology. 128(3):569–576 1999.
Molekul research summary: https://molekul.io/research/dalargin-receptors-1999. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry